Telmisartan for the management of patients at high cardiovascular risk

References

• Mathers CD, Loncar D. Projects of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Ezzati M. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003;362:271-80
   PubMed Web of Science ®Google Scholar
• Petersen S, Peto V, Rayner M, et al. European Cardiovascular Disease Statistics. BHF: London, 2005
   Google Scholar
• Leal J, Luengo-Fernández R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-19
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander Hoom S, Rodgers A; International Society of Hypertension. Global burden of blood pressure-related disease, 2001. Lancet 2008;371:1513-18
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206
   PubMed Web of Science ®Google Scholar
• Capewell S, Murphy NF, MacIntyre K, et al. Short-term and long-term outcomes in 133,429 emergency patients admitted with angina or myocardial infarction in Scotland, 1990–2000: population-based cohort study. Heart 2006;92:1563-70
   PubMed Web of Science ®Google Scholar
• Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006;66:641-6
   PubMed Web of Science ®Google Scholar
• Cea-Calvo L, Conthe P, Gómez-Fernández-Pérez C; RICARHD Investigators. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cardiovasc Diabetol 2006;5:23
   Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850-70
   PubMed Web of Science ®Google Scholar
• Bakris G, Böhm M, Dagenais G, et al. Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clin Res Cardiol 2008;97:713-25
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-88
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Staessen JA, Li Y, Thijs L, et al. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 2005;28:385-407
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
   PubMed Web of Science ®Google Scholar
• Wong ND, Lopez VA, L’Italien G, et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 2007;167:2431-6
   PubMed Web of Science ®Google Scholar
• Mustone Alexander L. Desirable therapeutic characteristics of an optimal antihypertensive agent. Drugs 2006;66:1239-52
   PubMed Web of Science ®Google Scholar
• Mulcahy D. Circadian variation in cardiovascular events. Blood Press Monit 1998;3:29-34
   PubMedGoogle Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin–angiotensin system and cardiovascular risk. Lancet 2007;369:1208-19
   PubMed Web of Science ®Google Scholar
• Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
   PubMed Web of Science ®Google Scholar
• Morawietz H. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS Trial. Circulation 2006;114:1S-296S
   Web of Science ®Google Scholar
• Unger T. The role of the renin–angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002;89(Suppl):3A-10A
   PubMedGoogle Scholar
• Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-92
   PubMed Web of Science ®Google Scholar
• Chen R, Iwai M, Wu L, et al. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 2003;42:542-7
   PubMed Web of Science ®Google Scholar
• Hanon S, Vijayaraman P, Sonnenblick EH, et al. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure. J Renin Angiotensin Aldosterone Syst 2000;1:147-50
   PubMedGoogle Scholar
• Crowley SD, Gurley SB, Coffman TM. AT(1) receptors and control of blood pressure: the kidney and more… Trends Cardiovasc Med 2007;17:30-4
   PubMed Web of Science ®Google Scholar
• Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol 2003;31:359-72
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter of love and hate. Peptides 2005;26:1401-9
   PubMed Web of Science ®Google Scholar
• Ahimastos AA, Natoli AK, Lawler A, et al. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45:1194-9
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-8
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):169S-73S
   PubMed Web of Science ®Google Scholar
• Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension 2008;51:1624-30
   PubMed Web of Science ®Google Scholar
• Weber MA, Messerli FH. Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension 2008;51:1465-7
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842-7
   PubMed Web of Science ®Google Scholar
• Morimoto T, Gandhi TK, Fiskio JM, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004;10:499-509
   PubMed Web of Science ®Google Scholar
• Chaput AJ. Persistence with angiotensin receptor blockers (ARB) versus other antihypertensives (AHT) using the Saskatchewan database. Can J Cardiol 2000;16(Suppl F):194A
   Google Scholar
• Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66
   PubMed Web of Science ®Google Scholar
• ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   Google Scholar
• Kakuta H, Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6
   PubMedGoogle Scholar
• Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-67
   PubMed Web of Science ®Google Scholar
• Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press Suppl 2001;1:6-11
   PubMedGoogle Scholar
• Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002;302:1089-95
   PubMed Web of Science ®Google Scholar
• Burnier M. Telmisartan: a different angiotensin receptor blocker protecting a different population? J Int Med Res 2009;37:1662-79
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Türck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C] telmisartan in healthy volunteers. J Clin Pharmacol 2000;40(12 Pt 1):1312-22
   PubMed Web of Science ®Google Scholar
• Bakris G, Burgess E, Weir M, et al.; AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-9
   Google Scholar
• Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003;348:2407-15
   PubMed Web of Science ®Google Scholar
• Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005;111:1777-83
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Neutel JM, Davidai G, et al. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006;19:104-12
   PubMed Web of Science ®Google Scholar
• Sharma AM, Davidson J, Koval S, et al. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol 2007;6:28
   PubMed Web of Science ®Google Scholar
• White WB, Davidai G, Schumacher H. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1–2 hypertension. J Hum Hypertens 2009;23:817-25
   PubMed Web of Science ®Google Scholar
• Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin Ther 2005;27:1795-805
   PubMed Web of Science ®Google Scholar
• Littlejohn 3rd TW, Majul CR, Olvera, R et al.; Study Investigators. Results of treatment with telmisartan–amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13
   Google Scholar
• Neutel JM, et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study. J Clin Hypertens 2010;7:537
   Google Scholar
• White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1–2 hypertension. Blood Press Monit 2010;15:205-12
   PubMed Web of Science ®Google Scholar
• Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
   PubMed Web of Science ®Google Scholar
• Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239-45
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-24
   PubMed Web of Science ®Google Scholar
• Costa FV, Esposti LD, Cerra C, et al. Trends in prescription and determinants of persistence to antihypertensive therapy. The PAPEETE Study. High Blood Press Cardiovasc Prev 2009;16:1-10
   Google Scholar
• Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008;1:32-40
   PubMedGoogle Scholar
• Electronic Medicines Compendium (eMC). Summary of Product Characteristics. Available at: http://emc.medicines.org.uk
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics. Available at: http://www.emea.europa.eu
   Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53
   Google Scholar
• TRANSCEND Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-83
   Google Scholar